Clinical utility of 18F-DOPA-PET in movement disorders. A systematic review

Puñal-Riobóo, Janet; Serena-Puig, A.; Varela-Lema, Leonor; Álvarez-Páez, A.M.; Ruano-Raviña, Alberto

doi:10.1016/s1578-200x(09)70018-x

Cited by 9 publications

(13 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our findings are in agreement with previous studies showing an inverse relationship between striatal 18 F‐dopa K i and motor severity . However, we found that negative correlations between motor severity and striatal 11 C‐PE2I BP ND were overall stronger than the analogous 18 F‐dopa K i correlations.…”

Section: Discussionsupporting

confidence: 92%

“…Positron emission tomography (PET) with 18 F‐dopa has long been regarded as the gold standard for measuring the integrity of dopaminergic nerve terminals and for assessing disease severity in PD patients . 18 F‐Dopa, a fluorinated analogue of l ‐dopa, follows the same presynaptic dopamine (DA) synthesis pathway, is decarboxylated by aromatic l ‐amino acid decarboxylase (AADC) and stored in presynaptic vesicles as 18 F‐labeled dopamine, thus providing an in vivo measurement of AADC activity and presynaptic DA storage capacity .…”

mentioning

confidence: 99%

See 1 more Smart Citation

¹¹C‐PE2I and ¹⁸F‐Dopa PET for assessing progression rate in Parkinson's: A longitudinal study

Lao–Kaim

Roussakis

et al. 2017

Movement Disorders

View full text Add to dashboard Cite

Striatal C-PE2I appears to show greater sensitivity for detecting differences in motor severity than F-dopa. Furthermore, dopamine transporter decline is closely associated with motor progression over time, whereas no such relationship was found with aromatic l-amino acid decarboxylase. C-PE2I may be more effective for evaluating the efficacy of neuroprotective treatments in PD. © 2017 International Parkinson and Movement Disorder Society.

show abstract

Section: Discussionsupporting

confidence: 92%

mentioning

confidence: 99%

¹¹C‐PE2I and ¹⁸F‐Dopa PET for assessing progression rate in Parkinson's: A longitudinal study

Lao–Kaim

Roussakis

et al. 2017

Movement Disorders

View full text Add to dashboard Cite

show abstract

“…Increasing amounts of tau, neurofilament (NF) protein and glial fibrillary acidic protein (GFAP) have been found in cerebrospinal fluid samples from PSP patients but these are usually common to the movement disorders in general. Functional imaging using positron emission tomography (PET) may show hypometabolism in the region of the frontal lobe in PSP but this feature may also not be specific to the disorder 30 . Nevertheless, criteria are available for diagnosing ‘possible’, ‘probable’ and ‘definite’ PSP based on clinical symptoms 31 .…”

Section: General Features Of Pspmentioning

confidence: 99%

“…Functional imaging using positron emission tomography (PET) may show hypometabolism in the region of the frontal lobe in PSP but this feature may also not be specific to the disorder. 30 Nevertheless, criteria are available for diagnosing 'possible', 'probable' and 'definite' PSP based on clinical symptoms. 31 Possible PSP is associated with a gradual progression of clinical symptoms in individuals older than 40 years accompanied by vertical supranuclear gaze palsy or a slowing of vertical saccades.…”

Section: Diagnosismentioning

confidence: 99%

Visual signs and symptoms of progressive supranuclear palsy

Armstrong

2011

Clinical and Experimental Optometry

View full text Add to dashboard Cite

Progressive supranuclear palsy is a rare, degenerative brain disorder and the second most common syndrome in which the patient exhibits 'parkinsonism', that is, a variety of symptoms involving problems with movement. General symptoms include difficulties with gait and balance; the patient walking clumsily and often falling backwards. The syndrome can be difficult to diagnose and visual signs and symptoms can help to separate it from closely related movement disorders such as Parkinson's disease, multiple system atrophy, dementia with Lewy bodies and corticobasal degeneration. A combination of the presence of vertical supranuclear gaze palsy, fixation instability, lid retraction, blepharospasm and apraxia of eyelid opening and closing may be useful visual signs in the identification of progressive supranuclear palsy. As primary eye-care practitioners, optometrists should be able to identify the visual problems of patients with this disorder and be expected to work with patients and their carers to manage their visual welfare.

show abstract

“…Accurate differential diagnosis not only is important for the management and treatment of individual patients but also must be considered in the design of prospective studies of the efficacy of new treatments intended to slow the progression of IPS (1). In several prospective PET studies, the integrity of the nigrostriatal dopamine pathway in IPS patients has been assessed with L-3,4-dihydroxy-6-18 Ffluoro-phenyl-alanine (2,3), but its utility for differential diagnosis of non-IPS is poorly documented (4).…”

mentioning

confidence: 99%

The Value of the Dopamine D_2/3 Receptor Ligand ¹⁸F-Desmethoxyfallypride for the Differentiation of Idiopathic and Nonidiopathic Parkinsonian Syndromes

Fougère¹,

Pöpperl²,

Xiong³

et al. 2010

J Nucl Med

View full text Add to dashboard Cite

We evaluated the utility of the selective dopamine D 2/3 receptor ligand 18 F-desmethoxyfallypride ( 18 F-DMFP) for the differential diagnosis of patients with idiopathic parkinsonian syndrome (IPS) and nonidiopathic parkinsonian syndrome (non-IPS). On the basis of the superior sensitivity of PET, we hypothesized that 18 F-DMFP should have properties for the differential diagnosis of these syndromes superior to what has been reported for the more conventional SPECT procedures. Methods: A series of 81 patients with parkinsonism (26 women, 55 men; mean age 6 SD, 68 6 11 y) were included in this retrospective analysis. A 30-min 18 F-DMFP PET recording was acquired starting 1 h after injection of the tracer (180-200 MBq, intravenously). The specific binding (SB) in divisions of the striatum was calculated relative to the occipital cortex using an observer-independent semiautomatic volume-of-interest-based technique. The optimal SB threshold was defined by means of receiver-operatingcharacteristic analysis, which was also used for the evaluation of the diagnostic performance of SB, ratios between striatal subregions, and absolute asymmetries in SB. Results: Significant differences (P , 0.001) were found in striatal SB between IPS and non-IPS, most notably in the posterior putamen, for which the diagnostic power for discrimination of IPS and non-IPS was the highest (sensitivity, 87%; specificity, 96%; and accuracy, 91%). A further gain of diagnostic power (sensitivity, 92%; specificity, 96%; and accuracy, 94%) was obtained through discriminant analysis combining 3 parameters: SB of the posterior putamen, the posterior-to-anterior putamen ratio, and the posterior putamen-to-caudate ratio. Conclusion: 18 F-DMFP PET is useful for the differential diagnosis of IPS and non-IPS in patients with parkinsonism. The findings are consistent with relative sparing of D 2/3 receptors in the dopamine-denervated putamen of IPS patients, in contrast to a more substantial loss of striatal dopamine receptors in non-IPS patients. The PET procedure for this differential diagnosis was superior to the reported experience with 123 I-iodobenzamide SPECT.

show abstract

Clinical utility of 18F-DOPA-PET in movement disorders. A systematic review

Cited by 9 publications

References 36 publications

¹¹C‐PE2I and ¹⁸F‐Dopa PET for assessing progression rate in Parkinson's: A longitudinal study

¹¹C‐PE2I and ¹⁸F‐Dopa PET for assessing progression rate in Parkinson's: A longitudinal study

Visual signs and symptoms of progressive supranuclear palsy

The Value of the Dopamine D_2/3 Receptor Ligand ¹⁸F-Desmethoxyfallypride for the Differentiation of Idiopathic and Nonidiopathic Parkinsonian Syndromes

Contact Info

Product

Resources

About

Clinical utility of 18F-DOPA-PET in movement disorders. A systematic review

Cited by 9 publications

References 36 publications

11C‐PE2I and 18F‐Dopa PET for assessing progression rate in Parkinson's: A longitudinal study

11C‐PE2I and 18F‐Dopa PET for assessing progression rate in Parkinson's: A longitudinal study

Visual signs and symptoms of progressive supranuclear palsy

The Value of the Dopamine D2/3 Receptor Ligand 18F-Desmethoxyfallypride for the Differentiation of Idiopathic and Nonidiopathic Parkinsonian Syndromes

Contact Info

Product

Resources

About

¹¹C‐PE2I and ¹⁸F‐Dopa PET for assessing progression rate in Parkinson's: A longitudinal study

¹¹C‐PE2I and ¹⁸F‐Dopa PET for assessing progression rate in Parkinson's: A longitudinal study

The Value of the Dopamine D_2/3 Receptor Ligand ¹⁸F-Desmethoxyfallypride for the Differentiation of Idiopathic and Nonidiopathic Parkinsonian Syndromes